Spray Drying of Amifostine
Amifostine is a cytoprotective agent used to reduce side effects of cancer therapies. Spray drying enables the production of stable, patient-friendly powders with optimized particle properties and bioavailability. It supports oral formulations with controlled release for improved therapeutic outcomes. Application Note No. 427 provides starting parameters, formulations, and results, including Amifostine/PLGA concentrations and solvent systems.
Probenkonzentration Amifostin/PLGA (0,4:1,0 und 1:1), Amifostin (400 mg/1 ml oder 1000 mg/2 ml) in deionisiertem Wasser und emulgiert in 50 ml Dichlormethan mit 1 g PLGA. Lösungsmittel Amifostin in Wasser, PLGA in DCM-Träger, Filmogen Poly (DL-Milchsäure-Glycolsäure) PLGA 50:50 (RG 502; intrinsische Viskosität 0,2 dL/g), Phosphatidylcholin (Tensid).